These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 31361272)
1. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy. Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272 [TBL] [Abstract][Full Text] [Related]
2. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment. Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527 [TBL] [Abstract][Full Text] [Related]
3. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa. Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149 [TBL] [Abstract][Full Text] [Related]
4. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study. Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753 [TBL] [Abstract][Full Text] [Related]
5. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia. Luwaya EL; Mwape L; Bwalya K; Siakabanze C; Hamooya BM; Masenga SK PLoS One; 2024; 19(9):e0308869. PubMed ID: 39241081 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique. Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381 [TBL] [Abstract][Full Text] [Related]
7. High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectional study. Mossoro-Kpinde CD; Gody JC; Mboumba Bouassa RS; Mbitikon O; Jenabian MA; Robin L; Matta M; Zeitouni K; Longo JD; Costiniuk C; Grésenguet G; Touré Kane NC; Bélec L Medicine (Baltimore); 2017 Mar; 96(10):e6282. PubMed ID: 28272247 [TBL] [Abstract][Full Text] [Related]
8. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. Meireles MV; Pascom ARP; Duarte EC; McFarland W AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860 [TBL] [Abstract][Full Text] [Related]
10. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582 [TBL] [Abstract][Full Text] [Related]
11. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463 [TBL] [Abstract][Full Text] [Related]
12. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA; Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460 [TBL] [Abstract][Full Text] [Related]
13. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. Ndashimye E; Avino M; Kyeyune F; Nankya I; Gibson RM; Nabulime E; Poon AFY; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ AIDS Res Hum Retroviruses; 2018 May; 34(5):404-414. PubMed ID: 29353487 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study. Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A; J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600 [TBL] [Abstract][Full Text] [Related]
15. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Steegen K; Levin L; Evans D; Technau KG; Hans L Pediatr Infect Dis J; 2022 Oct; 41(10):827-834. PubMed ID: 35895893 [TBL] [Abstract][Full Text] [Related]
16. No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference. Giacomelli A; Lai A; Franzetti M; Maggiolo F; Di Giambenedetto S; Borghi V; Francisci D; Magnani G; Pecorari M; Monno L; Vicenti I; Lepore L; Lombardi F; Paolucci S; Rusconi S; Antiviral Res; 2019 Dec; 172():104635. PubMed ID: 31629714 [TBL] [Abstract][Full Text] [Related]
17. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale. Kouamou V; Machekano R; Mapangisana T; Maposhere C; Munyati S; Mutsvangwa J; Shamu T; McCarty K; Katzenstein D; Manasa J AIDS Res Hum Retroviruses; 2022 Oct; 38(10):774-778. PubMed ID: 35959737 [TBL] [Abstract][Full Text] [Related]
18. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G AIDS; 2021 Jul; 35(9):1423-1432. PubMed ID: 33973876 [TBL] [Abstract][Full Text] [Related]
19. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567 [TBL] [Abstract][Full Text] [Related]